Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial

Related articles

1. Circulating tumour DNA-guided second-line targeted therapy for patients with metastatic colorectal cancer after failure of first-line cetuximab-based treatment: A prospective, phase II trial

   This article has 14 authors:

   1. Jianling Zou
   2. Wentao Yang
   3. Yingying Liu
   4. Wenhua Li
   5. Jieyun Zhang
   6. Qirong Geng
   7. Jinjia Chang
   8. Xiaolin Zhu
   9. Mingzhu Huang
   10. Chenchen Wang
   11. Xin Hu
   12. Xiaodong Zhu
   13. Weijian Guo
   14. Zhiyu Chen

2. Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicentre, single-arm, phase II trial

   This article has 36 authors:

   1. Dan Cao
   2. Ke Cheng
   3. Chenyan Zhang
   4. Jiaxin Liu
   5. Huanji Xu
   6. Jitao Zhou
   7. Zixing Huang
   8. Qingqiu Wu
   9. Yi Zhang
   10. Ping Chen
   11. Weikang Shao
   12. Zhiping Li
   13. Ye Chen
   14. Gang Zhao
   15. Cheng Yi
   16. Yu Yang
   17. Xin You
   18. Wenhao Guo
   19. Xiaofen Li
   20. Wanting Hou
   21. Xiaoying Li
   22. Qingqing Leng
   23. Hao Wei
   24. Pei Zhang
   25. Chen Chang
   26. Heqi Yang
   27. Ruizhen Li
   28. Xiaorui Zhu
   29. Xiangbin Zhang
   30. Renming Zhong
   31. Bole Tian
   32. Junjie Xiong
   33. Du He
   34. Wenwu Ling
   35. Rui Wang
   36. Chengjian Zhao

3. Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial

   This article has 3 authors:

   1. Marta Ostrowska-Leśko
   2. Radosław Mądry
   3. Marcin Bobiński